Exelixis (EXEL) Hisse Fiyat
Exelixis Fiyat
Exelixis, son 19 yılda gelirini yıllık %18,1 artırarak 2,32 Md USD seviyesine taşıdı. Hisse başına kâr, son 14 yılda yıllık %11,8 büyüdü. Exelixis için net marj, %33,7 ile birkaç yıl önceki %16,1 seviyesine göre yükseldi. Exelixis için 12 aylık konsensüs fiyat hedefi 52,00 USD; bu, hissenin bugünkü fiyatının yaklaşık %24,3 altında bir seviyeye denk geliyor. 24 analistten 11 tanesi hisse için alım öneriyor — genel konsensüs: Tut.
Exelixis hisse senedi fiyatı
Bu verilere Eulerpool API üzerinden ulaşın
Ayda 100.000 ücretsiz istek · kredi kartı yok
Exelixis iş modeli ve hisse analizi
Exelixis hakkında sık sorulan sorular
The business model of Exelixis Inc is focused on the development, commercialization, and discovery of therapies for the treatment of cancer. The company primarily engages in the research and development of small molecule therapies, targeting specific pathways that contribute to the growth and spread of cancer cells. Exelixis Inc aims to bring innovative and effective cancer treatments to patients by leveraging its expertise in drug discovery and development. The company collaborates with various partners, including pharmaceutical companies and research institutions, to advance its pipeline of potential oncology treatments.
Exelixis Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Exelixis Inc in the market are Bristol-Myers Squibb Co., Merck & Co. Inc., and Pfizer Inc.
Exelixis Inc. is a biotechnology company founded in 1994, headquartered in Alameda, California. The company focuses on the discovery, development, and commercialization of novel therapies to treat cancer and other serious diseases. With a strong emphasis on precision medicine, Exelixis aims to improve patients' lives through targeted therapies. Throughout its history, Exelixis has made significant advancements in drug development and has brought several innovative medicines to market. Notably, the company's flagship product, CABOMETYX® (cabozantinib), has been approved for the treatment of various cancers. Exelixis continues to invest in research and development, collaborating with partners to expand its pipeline and deliver new treatments to patients worldwide.
Exelixis Inc, a renowned biotechnology company, has achieved significant milestones in its journey. Notably, the company secured a major breakthrough with the FDA approval of its flagship product, Cabometyx, for the treatment of advanced renal cell carcinoma. Additionally, Exelixis Inc successfully expanded Cabometyx's indications to include advanced hepatocellular carcinoma, solid tumors, and differentiated thyroid cancer. The company also witnessed positive clinical trial results, demonstrating the efficacy of Cabometyx in several cancer types. Exelixis Inc's continuous dedication to research and development has propelled it to become a leading name in the pharmaceutical industry, revolutionizing cancer treatment with groundbreaking therapies.
Exelixis Inc is primarily present in the United States, focusing on developing and commercializing innovative medicines. Based in Alameda, California, the company's operations extend across the nation. Exelixis Inc has established strategic partnerships and collaborations worldwide, engaging in research and development efforts with renowned institutions and organizations globally.
Exelixis Inc represents values of innovation, collaboration, and commitment to improving patients' lives. With a focus on discovering and developing small molecule drugs, the company strives for scientific excellence in bringing groundbreaking therapies to market. Exelixis Inc is dedicated to advancing the field of oncology with their portfolio of targeted medicines, addressing the unmet needs of cancer patients. By fostering partnerships and working closely with the medical community, Exelixis Inc believes in the power of collaboration to drive meaningful progress in the fight against cancer.
Analistler şu anda Exelixis hissesi için ortalama 51,78 USD hedef fiyat belirliyor (medyan: 52,00 USD); bu, son fiyata göre -28,8 % anlamına gelir. Konsensüs 24 analist notuna dayanır.
24 analist şu anda Exelixis hissesini değerlendiriyor: 11 al, 12 tut, 1 sat öneriyor. 2026 için analistler Exelixis şirketinin 2,56 Md USD gelir ve 3,71 USD hisse başına kâr üretmesini bekliyor.
Güncel döviz kuruyla Exelixis hissesi 61,18 EUR (68,71 USD) seviyesindedir.
Exelixis hissesi (EXEL) 8 borsada işlem görür, bunlar arasında: NASDAQ (EXEL), London (0IJO.L), SIX (Zürich) (EX9.SW), XETRA (EX9.DE), Frankfurt (EX9.F), München (EX9.MU), Düsseldorf (EX9.DU).
Exelixis Inc. is a biopharmaceutical company specializing in the research, development, and marketing of drugs for the treatment of cancer. The company is headquartered in Alameda, California, USA. The business model of Exelixis is based on three pillars: research and development, product marketing and licensing, and collaborations and partnerships with other pharmaceutical companies. Research and development involve the discovery of new compounds and therapies for the treatment of cancer. Exelixis specializes in identifying signaling pathways that are important for the survival and growth of tumor cells. The company has an extensive pipeline of cancer drugs in various stages of development. The most well-known product of Exelixis is Cabozantinib, which is approved for the treatment of kidney cancer and thyroid cancer. Exelixis markets its products through its own sales organization in the USA and through partnerships with other companies worldwide. The company aims to expand its presence in the USA and other countries to increase revenue and profits. Exelixis also works closely with other pharmaceutical companies to acquire licenses for new technologies and products, and to form partnerships for the joint development and marketing of drugs. These collaborations can help accelerate Exelixis' research and development efforts and bring its products to market faster. In summary, the business model of Exelixis Inc. is based on the research, development, and marketing of cancer drugs. The company engages in extensive research and development, has a pipeline of drugs in various stages of development, and collaborates with other companies to acquire new technologies and products and form partnerships for the joint development and marketing of drugs. Exelixis aims to expand its presence in the US and international markets to increase its revenue and profit.
beklenen'nin Exelixis hasılatı 2,56 Md USD'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.
beklenen'nin Exelixis karı 1,05 Md USD'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.
Exelixis'nin Fiyat/Kazanç (F/K) oranı şu anda 18,51'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların Exelixis hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.
Exelixis'nin Fiyat/Satış (F/S) oranı şu anda 7,58'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve Exelixis hisse senedinin değerleme metriği olarak hizmet eder.
Exelixis'nin Eulerpool Kalite Puanı 8/10'dur.
Exelixis'nin ISIN'i US30161Q1040'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.
Exelixis'nin WKN'i 936718'dir. WKN (Wertpapierkennnummer), menkul kıymetleri tanımlamak için kullanılan altı haneli bir Alman kimlik numarasıdır.
Exelixis'nin ticker'ı EXEL'dir. Ticker sembolü, Exelixis hisseleri borsada işlem görmek için kullanılır.
Exelixis Hissesi
Exelixis Emsaller Grubu
Exelixis Ticker
Exelixis FIGI
Exelixis'nin tüm temel göstergeleri ve derinlemesine analizi
Exelixis hissesine yönelik aktienanalizimiz, satış, kar, P/E oranı, P/S oranı, EBIT gibi önemli mali kriterleri içermekte olup, dividende bilgilerini de ele almaktadır. Ayrıca, hisseler, piyasa değeri, borçlar, özsermaye ve Exelixis şirketin yükümlülükleri gibi konuları incelemekteyiz. Bu konular hakkında daha detaylı bilgilere ihtiyacınız varsa, web sitemizin alt sayfalarında kapsamlı analizler sunuyoruz: